Douglas Fosselman, MD
Internal Medicine · Westerville, OHNPI 1679556229
Payments from drug & device makers
Across 316 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$812
- Novo Nordisk$592
- GSK$495
- Pfizer$474
- AstraZeneca$395
- Lilly USA, LLC$274
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,84799%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $812 |
| Novo Nordisk | 41 | $592 |
| GSK | 38 | $495 |
| Pfizer | 24 | $474 |
| AstraZeneca | 26 | $395 |
| Lilly USA, LLC | 17 | $274 |
| Abbott | 10 | $167 |
| Amgen | 9 | $166 |
| Novartis | 8 | $137 |
| Amarin Pharma, Inc. | 24 | $131 |
| Exact Sciences | 6 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Xeris Pharmaceuticals, Inc. | 5 | $106 |
| Merck | 7 | $93 |
| Bayer | 5 | $86 |
| Johnson & Johnson | 5 | $72 |
| Boehringer Ingelheim | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Dexcom, Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Astellas Pharma US Inc | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 4 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| QOL Medical, LLC | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $30 |
| Edwards Lifesciences | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| BD | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
| Neos Therapeutics, LP | 1 | $13 |
How this compares
$4,882 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 78 | $100,684 |
| EliquisApixaban | 84 | $99,251 |
| JardianceEmpagliflozin | 58 | $73,808 |
| OzempicSemaglutide | 18 | $37,710 |
| FarxigaDapagliflozin Propanediol | 30 | $35,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $19,415 |
| ProliaDenosumab | 11 | $19,103 |
| MounjaroTirzepatide | 16 | $15,399 |
| VascepaIcosapent Ethyl | 19 | $11,093 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,817 |
| Carvedilol ErCarvedilol Phosphate | 12 | $7,201 |
| Testosterone | 37 | $5,430 |
| Celecoxib | 130 | $4,694 |
| Atorvastatin Calcium | 397 | $4,259 |
| Rosuvastatin Calcium | 403 | $3,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $72 | $100,68478 claims |
| PfizerEliquis | $474 | $99,25184 claims |
| Boehringer IngelheimJardiance | $66 | $73,80858 claims |
| Novo NordiskOzempic | $592 | $37,71018 claims |
| AstraZenecaFarxiga | $395 | $35,51030 claims |
| GSKTrelegy Ellipta, Shingrix | $495 | $22,97532 claims |
| AmgenProlia | $166 | $19,10311 claims |
| Lilly USA, LLCMounjaro | $274 | $15,39916 claims |
| AbbVieSynthroid | $812 | $3,24871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Westerville
- Nina DeepWesterville$614K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.